검색어 : 통합검색[Vanderbilt Tom]
총 377건 중 377건 출력
, 37/38 페이지
-
361
- The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics
- Wheeler, David C; Stefansson, Bergur V; Batiushin, Mikhail; Bilchenko, Oleksandr; Cherney, David Z I; Chertow, Glenn M; Douthat, Walter; Dwyer, Jamie P; Escudero, Elizabeth; Pecoits-Filho, Roberto; Furuland, Hans; Gó rriz, José Luis; Greene, Tom; Haller, Hermann; Hou, Fan Fan; Kang, Shin-Wook; Isidto, Rey; Khullar, Dinesh; Mark, Patrick B; McMurray, John J V; Kashihara, Naoki; Nowicki, Michal; Persson, Frederik; Correa-Rotter, Ricardo; Rossing, Peter; Toto, Robert D; Umanath, Kausik; Van Bui, Pham; Wittmann, Istvá n; Lindberg, Magnus; Sjö strö m, C David; Langkilde, Anna Maria; Heerspink, Hiddo J L; Department of Renal Medicine, University College London , London, UK; Late-Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca , Gothenburg, Sweden; Department of Nephrology, Rostov State Medical University , Rostov, Russia; Kharkiv Medical Academy of Postgraduate Education , Kharkiv, Ukraine; Toronto General Hospital Research Institute, University Health Network , Toronto, ON, Canada; Department of Epidemiology and Population Health, Stanford University School of Medicine , Stanford, CA, USA; Department of Nephrology, Hospital Privado Universitario de Cordoba , Cordoba, Argentina; Vanderbilt University Medical Center , Nashville, TN, USA; Division of Nephrology, Hospital Arzobispo Loayza, Cayetano Heredia University , Lima, Peru; School of Medicine, Pontif; (Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, v.35, 2020, pp.1700-1711)
-
362
- The association between genetically elevated polyunsaturated fatty acids and risk of cancer
- Haycock, Philip C.; Borges, Maria Carolina; Burrows, Kimberley; Lemaitre, Rozenn N.; Burgess, Stephen; Khankari, Nikhil K.; Tsilidis, Konstantinos K.; Gaunt, Tom R.; Hemani, Gibran; Zheng, Jie; Truong, Therese; Birmann, Brenda M.; OMara, Tracy; Spurdle, Amanda B.; Iles, Mark M.; Law, Matthew H.; Slager, Susan L.; Saberi Hosnijeh, Fatemeh; Mariosa, Daniela; Cotterchio, Michelle; Cerhan, James R.; Peters, Ulrike; Enroth, Stefan; Gharahkhani, Puya; Le Marchand, Loic; Williams, Ann C.; Block, Robert C.; Amos, Christopher I.; Hung, Rayjean J.; Zheng, Wei; Gunter, Marc J.; Smith, George Davey; Relton, Caroline; Martin, Richard M.; MRC Integrative Epidemiology Unit (IEU), Population Health Sciences, University of Bristol, Bristol, United Kingdom; MRC Integrative Epidemiology Unit (IEU), Population Health Sciences, University of Bristol, Bristol, United Kingdom; MRC Integrative Epidemiology Unit (IEU), Population Health Sciences, University of Bristol, Bristol, United Kingdom; Department of Medicine, Cardiovascular Health Research Unit, University of Washington, Seattle, WA, USA; MRC Biostatistics Unit, University of Cambridge, USA; Division of Genetic Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA; Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK; MRC Integrative Epidemiology Unit (IEU), Population Health Sciences, University of Bristol, Bristol, United Kingdom; MRC Integrative Epidemiology Unit (IEU), Population Health Sciences, University of Bristol, Bristol, United Kingdom; Department of Endocrine and; (EBioMedicine, v.91, 2023, pp.104510)
-
363
- Case Series of Thrombosis With Thrombocytopenia Syndrome After COVID-19 Vaccination-United States, December 2020 to August 2021
- See, Isaac; Lale, Allison; Marquez, Paige; Streiff, Michael B.; Wheeler, Allison P.; Tepper, Naomi K.; Woo, Emily Jane; Broder, Karen R.; Edwards, Kathryn M.; Gallego, Ruth; Geller, Andrew I.; Jackson, Kelly A.; Sharma, Shashi; Talaat, Kawsar R.; Walter, Emmanuel B.; Akpan, Imo J.; Ortel, Thomas L.; Urrutia, Victor C.; Walker, Shannon C.; Yui, Jennifer C.; Shimabukuro, Tom T.; Mba-Jonas, Adamma; Su, John R.; Shay, David K.; Centers for Disease Control and Prevention COVID-19 Response Team, Atlanta, Georgia (I.S., A.L., P.M., N.K.T., K.R.B., R.G., A.I.G., K.A.J., S.S., T.T.S., J.R.S., D.K.S.); Centers for Disease Control and Prevention COVID-19 Response Team, Atlanta, Georgia (I.S., A.L., P.M., N.K.T., K.R.B., R.G., A.I.G., K.A.J., S.S., T.T.S., J.R.S., D.K.S.); Centers for Disease Control and Prevention COVID-19 Response Team, Atlanta, Georgia (I.S., A.L., P.M., N.K.T., K.R.B., R.G., A.I.G., K.A.J., S.S., T.T.S., J.R.S., D.K.S.); The Johns Hopkins University, Baltimore, Maryland (M.B.S., K.R.T., V.C.U., J.C.Y.); Vanderbilt University Medical Center, Nashville, Tennessee (A.P.W., K.M.E., S.C.W.); Centers for Disease Control and Prevention COVID-19 Response Team, Atlanta, Georgia (I.S., A.L., P.M., N.K.T., K.R.B., R.G., A.I.G., K.A.J., S.S., T.T.S., J.R.S., D.K.S.); Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, Maryland (E.J.W., A.M.); Centers for Disease; (Annals of internal medicine, v.175, 2022, pp.513-522)
-
364
- HER2-enriched subtype and ERBB2 mRNA as predictors of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer: A combined analysis of TBCRC006/023 and PAMELA trials.
- Prat, Aleix; De Angelis, Carmine; Pascual, Tomà ¡s; Gutierrez, Carolina; Llombart-Cussac, Antonio; Wang, Tao; Cortes, Javier; Rexer, Brent Neil; Veeraraghavan, Jamunarani; Forero-Torres, Andres; Wolff, Antonio C.; Morales, Serafin; Krop, Ian E.; Pavlick, Anne Clarisse; Bermejo, Begona; Hilsenbeck, Susan G.; Oliveira, Mafalda; Schiff, Rachel; Osborne, C. Kent; Rimawi, Mothaffar F.; Department of Medical Oncology, Hospital Clinic, Barcelona, Spain; ; Bayolor College of Medicine, Houston, TX; ; Department of Medical Oncology, Hospital Clí nic of Barcelona, Barcelona, Spain; ; Baylor College of Medicine, Houston, TX; ; Hospital Arnau Vilanova, Valencia, Spain; ; Baylor College of Medicine, Houston, TX; ; Vall d’Hebron University Hospital Institute of Oncology (VHIO), Barcelona, Spain; ; Vanderbilt University Medical Center, Nashville, TN; ; Breast Center Baylor College of Medicine, Houston, TX; ; University of Alabama at Birmingham, Birmingham, AL; ; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD; ; Medical Oncology Department, Hospital Universitario Arnau de Vilanova de Lleida, Lleida, Spain; ; Dana-Farber Cancer Institute, Boston, MA; ; Baylor College of Medicine, Houston, TX; ; Hospital Clinico Universitario de Valencia; Centro de Investigació n Biomé dica en Red de Oncologí a; CIBERONC-ISCIII; (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, v.36, 2018, pp.509-509)
-
365
- Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma
-
Oluwole, Olalekan O.;
Bouabdallah, Krimo;
Muñ
oz, Javier;
De Guibert, Sophie;
Vose, Julie M.;
Bartlett, Nancy L.;
Lin, Yi;
Deol, Abhinav;
McSweeney, Peter A.;
Goy, Andre H.;
Kersten, Marie José
;
Jacobson, Caron A.;
Farooq, Umar;
Minnema, Monique C.;
Thieblemont, Catherine;
Timmerman, John M.;
Stiff, Patrick;
Avivi, Irit;
Tzachanis, Dimitrios;
Kim, Jenny J.;
Bashir, Zahid;
McLeroy, Jeff;
Zheng, Yan;
Rossi, John M.;
Johnson, Lisa;
Goyal, Lovely;
van Meerten, Tom;
Vanderbilt‐
Ingraham Cancer Center, Nashville, TN, USA;
Service d'Hé
matologie et Thé
rapie Cellulaire, CHU Bordeaux, Bordeaux, France;
Banner MD Anderson Cancer Center, Gilbert, AZ, USA;
Hô
pital de Pontchaillou, Rennes, France;
University of Nebraska Medical Center, Omaha, NE, USA;
Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA;
Mayo Clinic, Rochester, MN, USA;
Karmanos Cancer Center, Wayne State University, Detroit, MI, USA;
Colorado Blood Cancer Institute, Denver, CO, USA;
John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA
-
366
- Belzutifan plus lenvatinib for patients (pts) with advanced clear cell renal cell carcinoma (ccRCC) after progression on a PD-1/L1 and VEGF inhibitor: Preliminary results of arm B5 of the phase 1/2 KEYMAKER-U03B study.
- Albiges, Laurence; Beckermann, Katy; Miller, Wilson H.; Goh, Jeffrey C.; Gajate, Pablo; Harris, Carole A.; Suá rez, Cristina; Peer, Avivit; Park, Se Hoon; Stadler, Walter Michael; Weickhardt, Andrew James; Faust, Guy; Fong, Peter C.C.; Waddell, Tom; Venugopal, Balaji; Yin, Lina; Wang, Ding; Perini, Rodolfo F.; Powles, Thomas; Gustave Roussy, Villejuif, France; Vanderbilt University, Nashville, TN; Jewish General Hospital, Montré al, QC, Canada; Queensland Health, Brisbane, Australia; Ramó n y Cajal University Hospital, Madrid, Spain; UNSW Sydney, Sydney, Australia; Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain; Rambam Health Care Campus, Haifa, Israel; Samsung Medical Center, Seoul, South Korea; University of Chicago, Chicago, IL; Olivia Newton John Cancer Research Institute, Heidelberg, Australia; University Hospitals of Leicester National Health Service Trust, Leicester, United Kingdom; Auckland City Hospital and University of Auckland, Auckland, New Zealand; Christie Hospital, Manchester, United Kingdom; University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; Merck & Co., Inc., Rahway, NJ; Merck & Co., Inc., Rahway, NJ; Merck & Co., Inc., Rahway, NJ; Barts Health NHS Trust and the Royal Free NHS Foundation Trust, Barts Cancer; (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, v.41, 2023, pp.4553-4553)
-
367
- Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): One-Year Follow-up of ZUMA-1 Cohort 6 (C6)
- Oluwole, Olalekan O.; Forcade, Edouard; Muñ oz, Javier; de Guibert, Sophie; Vose, Julie M.; Bartlett, Nancy L.; Lin, Yi; Deol, Abhinav; McSweeney, Peter A.; Goy, Andre H.; Kersten, Marie José ; Jacobson, Caron; Farooq, Umar; Minnema, Monique C.; Thieblemont, Catherine; Timmerman, John M.; Stiff, Patrick; Avivi, Irit; Tzachanis, Dimitrios; Kim, Jenny J.; Zheng, Yan; Shen, Rhine R.; Vardhanabhuti, Saran; Van Meerten, Tom; Vanderbilt-Ingram Cancer Center, Nashville, TN; CHU Bordeaux, Bordeaux, France; Banner MD Anderson Cancer Center, Gilbert, AZ; Hé matologie Clinique, CHU Rennes, Rennes, France; University of Nebraska Medical Center, Omaha, NE; Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO; Mayo Clinic, Rochester, MN; Karmanos Cancer Institute, Wayne State University, Detroit, MI; Colorado Blood Cancer Institute, Denver, CO; Hackensack University Medical Center, John Theurer Cancer Center, Hackensack, NJ; Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands; Dana-Farber Cancer Institute, Boston, MA; University of Iowa, Iowa City, IA; on behalf of HOVON/LLPC (Lunenburg Lymphoma Phase I/II Consortium), Utrecht, Netherlands; Hemato-Oncology Department, APHP, Saint-Louis Hospital, Paris, France; UCLA David Geffen School of Medicine, Los Angeles, CA; Loyola University Chicago Stritch School of Medicine, Maywood, IL; The Sackler Faculty of Med; (Blood, v.138, 2021, pp.2832-2832)
-
368
- Primary Analysis of ZUMA-7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma
- Locke, Frederick L.; Miklos, David B.; Jacobson, Caron; Perales, Miguel-Angel; Kersten, Marie José ; Oluwole, Olalekan O.; Ghobadi, Armin; Rapoport, Aaron P.; McGuirk, Joseph P.; Pagel, John M.; Muñ oz, Javier; Farooq, Umar; Van Meerten, Tom; Reagan, Patrick M.; Sureda, Anna; Flinn, Ian W.; Vandenberghe, Peter; Song, Kevin; Dickinson, Michael; Minnema, Monique C.; Riedell, Peter A.; Leslie, Lori A.; Chaganti, Sridhar; Yang, Yin; Filosto, Simone; Schupp, Marco; To, Christina; Cheng, Paul; Gordon, Leo I.; Westin, Jason R.; Moffitt Cancer Center, Tampa, FL; Stanford University School of Medicine, Stanford, CA; Dana-Farber Cancer Institute, Boston, MA; Memorial Sloan-Kettering Cancer Center, New York, NY; Amsterdam UMC, University of Amsterdam, Netherlands, on behalf of HOVON/LLPC, Amsterdam, Netherlands; Vanderbilt-Ingram Cancer Center, Nashville, TN; Washington University School of Medicine, Saint Louis, MO; The Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD; University of Kansas Cancer Center, Kansas City, KS; Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA; Banner MD Anderson Cancer Center, Gilbert, AZ; University of Iowa, Iowa City, IA; University Medical Center Groningen, Netherlands, on behalf of HOVON/LLPC, Groningen, Netherlands; University of Rochester School of Medicine, Rochester, NY; Hematology Department, Institut Català d'Oncologia-Hospitalet, IDIBELL, Universitat de B; (Blood, v.138, 2021, pp.2-2)
-
369
- Camtrap DP: an open standard for the FAIR exchange and archiving of camera trap data
- Bubnicki, Jakub W.; Norton, Ben; Baskauf, Steven J.; Bruce, Tom; Cagnacci, Francesca; Casaer, Jim; Churski, Marcin; Cromsigt, Joris P. G. M.; Farra, Simone Dal; Fiderer, Christian; Forrester, Tavis D.; Hendry, Heidi; Heurich, Marco; Hofmeester, Tim R.; Jansen, Patrick A.; Kays, Roland; Kuijper, Dries P. J.; Liefting, Yorick; Linnell, John D. C.; Luskin, Matthew S.; Mann, Christopher; Milotic, Tanja; Newman, Peggy; Niedballa, Jü rgen; Oldoni, Damiano; Ossi, Federico; Robertson, Tim; Rovero, Francesco; Rowcliffe, Marcus; Seidenari, Lorenzo; Stachowicz, Izabela; Stowell, Dan; Tobler, Mathias W.; Wieczorek, John; Zimmermann, Fridolin; Desmet, Peter; Mammal Research Institute, Polish Academy of Sciences Białowież a Poland; North Carolina Museum of Natural Sciences Raleigh North Carolina USA; Jean & Alexander Heard Libraries Vanderbilt University Nashville Tennessee USA; School of Biological Sciences University of Queensland Brisbane Queensland Australia; Animal Ecology Unit, Research and Innovation Centre Fondazione Edmund Mach San Michele all'Adige Italy; Research Institute for Nature and Forest (INBO) Brussels Belgium; Mammal Research Institute, Polish Academy of Sciences Białowież a Poland; Department of Wildlife, Fish, and Environmental Studies Swedish University of Agricultural Sciences Umeå Sweden; Animal Ecology Unit, Research and Innovation Centre Fondazione Edmund Mach San Michele all'Adige Italy; Wildlife Ecology and Management Albert‐ Ludwigs‐ Universitä t Freiburg Freiburg im Breisgau Germany; Wildlife and Terrestrial Ecosystems, Rocky Mountain Research Station, US Forest Se; (Remote sensing in ecology and conservation, v.10, 2024, pp.283-295)
-
370
- HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade
- Prat, Aleix; Pascual, Tomá s; De Angelis, Carmine; Gutierrez, Carolina; Llombart-Cussac, Antonio; Wang, Tao; Corté s, Javier; Rexer, Brent; Paré , Laia; Forero, Andres; Wolff, Antonio C; Morales, Serafí n; Adamo, Barbara; Brasó -Maristany, Fara; Vidal, Maria; Veeraraghavan, Jamunarani; Krop, Ian; Galvá n, Patricia; Pavlick, Anne C; Bermejo, Begoñ a; Izquierdo, Miguel; Rodrik-Outmezguine, Vanessa; Reis-Filho, Jorge S; Hilsenbeck, Susan G; Oliveira, Mafalda; Dieci, Maria Vittoria; Griguolo, Gaia; Fasani, Roberta; Nuciforo, Paolo; Parker, Joel S; Conte, PierFranco; Schiff, Rachel; Guarneri, Valentina; Osborne, C Kent; Rimawi, Mothaffar F; Department of Medical Oncology, Hospital Clí nic de Barcelona , Spain; Department of Medical Oncology, Hospital Clí nic de Barcelona , Spain; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine , Houston, TX; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine , Houston, TX; Department of Medical Oncology, Hospital Arnau de Vilanova , Valencia, Spain; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine , Houston, TX; IOB Institute of Oncology, Quironsalud Group, Madrid & Barcelona , Spain; Department of Medicine, Vanderbilt University , Nashville, TN; Department of Medical Oncology, Hospital Clí nic de Barcelona , Spain; Department of Medicine, University of Alabama-Birmingham , Birmingham, AL; Johns Hopkins University , Baltimore, MD; Department of Medical Oncology, Hospital Uni; (Journal of the National Cancer Institute: JNCI, v.112, 2020, pp.46-54)
QUICK MENU
